Study population characteristics.
| Characteristics | All Subjects, n = 90 | Active Subjects, n = 66 | Inactive Subjects, n = 24 | p |
|---|---|---|---|---|
| Age at study entry, yrs, median (IQR) | 11.5 (8.8, 14.5) | 11.0 (8.2, 13.9) | 12.9 (10.1, 16.1) | NS |
| Age at disease onset, yrs, median (IQR) | 7.9 (5.0, 10.0) | 8.0 (5.1, 10) | 7.0 (5.0, 9.1) | NS |
| Disease duration at study onset, yrs, median (IQR) | 2.8 (1.3, 5.0) | 2.1 (0.8, 4.4) | 4.4 (2.3, 7.2) | 0.004 |
| Duration in study, mos (IQR) | 5.6 (4.4, 6.8) | 5.5 (4.3, 6.5) | 6.3 (5.4, 7.2) | NS |
| Sex, F:M | 71:19 | 53:13 | 18:6 | NS |
| White | 70 (78) | 52 (79) | 18 (75) | NS |
| Linear scleroderma subtype | 55 (61) | 41 (62) | 14 (58) | NS |
| Limb/trunk | 44 (51.1) | 33 (50.0) | 11 (45.8) | |
| Head | 11 (11.1) | 8 (12.1) | 3 (12.5) | |
| Circumscribed morphea subtype | 35 (38.9) | 25 (37.9) | 10 (41.7) | NS |
| Superficial | 19 (21.1) | 14 (21.2) | 5 (20.8) | |
| Deep | 16 (17.8) | 11 (16.7) | 5 (20.8) | |
| Anatomic sites: Head | 14 (15.6) | 10 (15) | 4 (16.7) | NS |
| Trunk | 28 (31) | 21 (32) | 7 (29) | NS |
| Limb | 48 (53) | 35 (53) | 13 (54) | NS |
| ANA positivity | 38 (42) | 28 (42) | 10 (42) | NS |
| Extracutaneous morbidity | 50 (56) | 37 (56) | 13 (54) | NS |
| Prior treatment with MTX | 64 (71) | 42 (64) | 22 (92) | 0.001 |
| Prior treatment with corticosteroids | 55 (61) | 39 (59) | 16 (67) | NS |
Data are n (%) unless otherwised indicated. P values refer to results of tests of differences between active and inactive subjects reported by 2-sided Wilcoxon rank sum test or 2-sample t test. IQR: interquartile range; NS: not significant; MTX: methotrexate; ANA: antinuclear antibodies.